The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis

Francescutti,Valerie; Rivera,Louis; Seshadri,Mukund; Kim,Minhyung; Haslinger,Michelle; Camoriano,Marta; Attwood,Kristopher; Kane ,John  M.; Skitzki,Joseph J.

doi:10.3892/or.2013.2473

July 2013 Volume 30 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July 2013 Volume 30 Issue 1

Full Size Image

Article Open Access

The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis

Authors:
- Valerie Francescutti
- Louis Rivera
- Mukund Seshadri
- Minhyung Kim
- Michelle Haslinger
- Marta Camoriano
- Kristopher Attwood
- John M. Kane
- Joseph J. Skitzki
View Affiliations / Copyright

Affiliations: Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA, Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA

Copyright: © Francescutti et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].
Pages: 35-42
|
Published online on: May 15, 2013

https://doi.org/10.3892/or.2013.2473
Expand metrics +

Abstract

The clinical practice of hyperthermic intraperitoneal chemoperfusion (HIPEC) for carcinomatosis has lacked preclinical justification. A standardized mouse model was created to evaluate the independent effects of intraperitoneal chemotherapy. Diffuse colorectal carcinomatosis was generated in mice prior to intraperitoneal lavage with mitomycin C (MMC) at clinically comparable dosing for variable lengths of time. Tumor volumes, MMC tissue concentrations and survival were measured in comparison to saline lavage and intravenous MMC. Magnetic resonance imaging revealed a direct correlation between tumor volume, MMC dose and exposure time and survival. Intravenous MMC demonstrated a rapid clearance from the blood, lower peritoneal tissue concentrations, less tumor growth inhibition and decreased survival compared to intraperitoneal administration. Intraperitoneal chemotherapy inhibited tumor growth independent of cytoreduction or hyperthermia, demonstrated improved peritoneal tissue concentration and was associated with increased survival. These data support the clinical utility of the intraperitoneal chemotherapy component of HIPEC.

View Figures

View References

1	Koppe MJ, Boerman OC, Oyen WJ and Bleichrodt RP: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 243:212–222. 2006. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chu DZ, Lang NP, Thompson C, Osteen PK and Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 63:364–367. 1989. View Article : Google Scholar : PubMed/NCBI
4	Elias D, Delperro JR, Sideris L, et al: Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 11:518–521. 2004. View Article : Google Scholar
5	Sugarbaker PH: A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol. 32:S68–S73. 2005. View Article : Google Scholar : PubMed/NCBI
6	Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 22:3284–3292. 2004. View Article : Google Scholar
7	Verwaal VJ: Long-term results of cytoreduction and HIPEC followed by systemic chemotherapy. Cancer J. 15:212–215. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sugarbaker PH: Peritonectomy procedures. Surg Oncol Clin N Am. 12:703–727. xiii2003. View Article : Google Scholar : PubMed/NCBI
9	Rossi CR, Mocellin S, Pilati P, et al: Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am. 12:781–794. 2003. View Article : Google Scholar : PubMed/NCBI
10	van Ruth S, Verwaal VJ and Zoetmulder FA: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 12:771–780. 2003.
11	Klaver YL, Hendriks T, Lomme RM, Rutten HJ, Bleichrodt RP and de Hingh IH: Hyperthermia and intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis: an experimental study. Ann Surg. 254:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
12	Cohen MS, Al-Kasspooles MF, Williamson SK, Henry D, Broward M and Roby KF: Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. Ann Surg Oncol. 17:296–303. 2010. View Article : Google Scholar : PubMed/NCBI
13	Pelz JO, Doerfer J, Hohenberger W and Meyer T: A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis. BMC Cancer. 5:562005. View Article : Google Scholar
14	Bevanda M, Orsolic N, Basic I, et al: Prevention of peritoneal carcinomatosis in mice with combination hyperthermal intraperitoneal chemotherapy and IL-2. Int J Hyperthermia. 25:132–140. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zahedi P, De Souza R, Piquette-Miller M and Allen C: Docetaxel distribution following intraperitoneal administration in mice. J Pharm Pharm Sci. 14:90–99. 2011.PubMed/NCBI
16	Aarts F, Hendriks T, Boerman OC, Oyen WJ and Bleichrodt RP: Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin. Cancer Biother Radiopharm. 23:301–309. 2008. View Article : Google Scholar
17	Hartmann J, Kilian M, Atanassov V, Braumann C, Ordemann J and Jacobi CA: First surgical tumour reduction of peritoneal surface malignancy in a rat’s model. Clin Exp Metastasis. 25:445–449. 2008.PubMed/NCBI
18	Bouquet W, Deleye S, Staelens S, et al: Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res. 28:1653–1660. 2011. View Article : Google Scholar : PubMed/NCBI
19	Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E and Querleu D: Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study. Ann Surg Oncol. 15:339–344. 2008. View Article : Google Scholar
20	Muller H, Hahn M, Weller L and Simsa J: Strategies to reduce perioperative morbidity in cytoreductive surgery. Hepatogastroenterology. 55:1523–1529. 2008.PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

The benefit of intraperitoneal chemotherapy for the treatment of colorectal carcinomatosis

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Related Articles